Nicolas U Gerber

9PUBLICATIONS
179CO-AUTHORS
Haematological tumoursMolecular targetsCentral nervous systemLiquid biopsiesPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Dec 12, 2025
Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial.

Juliet C Gray, Rebekah Weston, Cormac Owens

|Apr 16, 2025
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.

Lindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford

|Dec 03, 2024
Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions.

Audrey-Anne Lamoureux, Michael J Fisher, Lauriane Lemelle

|Mar 12, 2024
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.

Lindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford

|Jan 08, 2024
Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial.

Lucas Moreno, Rebekah Weston, Cormac Owens

|Nov 18, 2023
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.

Lindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford

Pageof 2

Frequent Collaborators

5 joint publications

Ruth Witt

5 joint publications

Karsten Nysom

4 joint publications

Nicholas G Gottardo

4 joint publications

Jordan R Hansford